Orby Pharmacy | The Daily News | The Daily News serving Huntingdon, Mount Union, Orbisonia, and Saxton PA HuntingdonDailyNews ORBY PHARMACY Water Street, Orbisonia • 447-3934 PHARMACY TOPICS by Jim Rathke, R.Ph. Results from a new study presented at the International Liver CongressTM 2017 found that OPDIVO® (nivolumab), an immuno- oncology drug which acts by modulating the immune system, improves long-term survival rates of pa- tients with liver cancer, regardless of whether or not patients were infected with Hepatitis B or C. Liver cancer, or hepatocel- lular carcinoma (HCC), is the second most common cause of cancer-related deaths worldwide. The prognosis for patients with advanced liver cancer is poor. The multikinase inhibitor, sorafenib, is the only approved systematic treatment. If the patient is not tolerant or has contraindictions for sorafenib therapy, there is no standard of care and therefore patients lack effective treatment options. Nivolumab has already in- creased survival time in different types of cancers, and has become an important treatment option for certain types of kidney, blood, melanoma and non-small cell lung cancer. Despite standard use for the itching associated with urticaria (commonly known as hives), prednisone (a steroid) offered no additional relief to emergency patients suffering from hives than a placebo did, according to a randomized, place- bo-controlled, double-blind, parallel-group study published in Annals of Emergency Medicine. Many classes of common antibiotics, such as macrolides, quinolones, tetracyclines, sulfonamides and metronidazole, were associated with an increased risk of miscarriage in early pregnancy, according to a new study published in CMAJ (Canadian Medical Association Journal). Erythromycin was not associated with increased risk nor was nitrofurantoin, often used to treat urinary tract infections in pregnant women. Brought to you as a public service by... Your family’s health headquarters WHEN YOUR DOCTOR PRESCRIBES THE BEST, WE DO THE REST.